Hereditary Hemorrhagic Telangiectasia (HHT) Center

Background
The Health Resources and Services Administration (HRSA) is accepting applications for the fiscal year (FY) 2022 Hereditary Hemorrhagic Telangiectasia (HHT) Center. The purpose of the program is to reduce morbidity and mortality associated with hereditary hemorrhagic telangiectasia by funding a national center to: 1) expand access to and coordination of care for HHT patients; and 2) develop a de-identified, aggregate data collection registry to better understand this rare disease and treatment outcomes.

Grant Details
Hereditary hemorrhagic telangiectasia (HHT) is a rare hereditary disorder that results in the development of abnormal blood vessels, impacting multiple organ systems and requiring care from numerous specialists. The program aims to increase the number of new patients seen by multidisciplinary HHT teams, ensure partner centers enter patient data into a data collection registry, and increase medical providers' knowledge about HHT and its treatment. The program also aims to address disparities in care for individuals with HHT, particularly those from underserved populations.

Eligibility Requirements
Any domestic public or private entity, including an Indian tribe or tribal organization, is eligible to apply. Domestic faith-based and community-based organizations are also eligible to apply.

Period of Performance
The period of performance is from September 30, 2022 through September 29, 2025 (3 years).

Grant Value
Up to $2,000,000 is available annually to fund one recipient. The actual amount available will be determined upon enactment of the final FY 2022 federal appropriation. The funding will be provided in the form of a cooperative agreement.